A comparison of side-effects and quality-of-life in patients operated on for prostate cancer with and without salvage radiation therapy

Figures & data

Figure 1. Consort diagram of this study.

Table 1. Patient and treatment characteristics.

	SRT group, n = 255	Reference group, n = 485
Heart disease, n (%)	36 (14)	93* (21)
Warfarin medication, n (%)	7 (3)	25* (5)
Diabetes, n (%)	25 (10)	52* (12)
Smoking, n (%)	15 (6)	20* (4)
Present ADT, n (%)	55 (22)	28* (6)
Age at surgery, median (IQR), years	62 (58–65)	62 (57–64)
Age at survey, median (IQR) years	72 (69–76)	72 (69–75)
Age at radiation, median (IQR) years	65 (62–68)	—
pT2, n (%)	81 (32)	304 (62)
pT3, n (%)	148 (58)	76 (16)
pTX, n (%)	25 (10)	103 (21)
Time from surgery to survey, median (IQR) years	10 (8–12)	10 (8–12)
Time from surgery to radiation, median (IQR) years	2.4 (1.3–4.0)	—
Time from radiation to survey, median (IQR) years	6.7 (5.3–8.2)	—
PTV, median (IQR) ml	168 (140–200)	—

*Response rate at HDF 461/485 = 95%.

Heart disease: “Do you suffer from a heart disease?”

Diabetes: “Do you suffer from diabetes?”

Smoking: “Do you smoke?”

Figure 2. Relative risk ratios and 95% confidence intervals for the risk of side-effects SRT versus reference group.

Figure 3. The intensity of symptoms and quality-of-life assessments when significant differences between SRT and reference were found. Percentage of total on column. Blue = SRT; Red = reference group. ‘1’ not at all, ‘2’ a little, ‘3’ to some extent, ‘4’’ very much.

Figure 4. (a) Relative risk, age at surgery, dichotomized at its median, SRT; (b) Relative risk, time to survey, dichotomized at its median, SRT; (c) Relative risk ratios and 95% confidence intervals for the risk of side-effects, PTV versus scores, SRT.